Missed argenx's Run? What Holders Had To Believe

argenx closed the period with a very real milestone, the FDA decision to broaden Vyvgart’s label to all adult generalized myasthenia gravis patients, while fresh Phase 3 data in autoimmune myositis and a planned Forte Biosciences acquisition pushed the story into new territory. Investors who held argenx over the past year are up 22.0%, including dividends. If you were weighing a purchase back on 2025-10-07, what exactly did you need to believe about Vyvgart’s future reach and argenx’s pipeline depth?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

The move put argenx in the middle of this trade. Scan 126 healthcare AI stocks for other companies exposed to it.

The Two argenx Stories Investors Had To Weigh

The shares cost €679 at the start of the period, so any argenx view had to start with whether that already reflected the big autoimmune opportunity being talked about.

The bullish narrative put fair value at €724, or 7% above the start price. It leaned on Vyvgart gaining new indications plus wider use of self-administered formats while revenue grew 31.7% with a 37.4% profit margin and a future P/E of 20.3x.

The cautious view set fair value at €528, or 22% below the start price. It focused on pricing pressure and biosimilar risk with revenue growth at 24.2%, margins at 26.8% and a future P/E of 28.7x.

What The Vyvgart Evidence Actually Tested For argenx

The FDA decision to broaden Vyvgart’s gMG label and Phase 3 success in autoimmune myositis leaned toward the bullish argenx story that assumed wider use across more patients and conditions. At the same time, revenue of $1.541b and net income of $472m in Q2 2026, with margin at 30.6%, gave the cautious view less support on profitability. Overall, the period backed the optimistic case.

The whole debate turned on how much real patient and indication expansion would show up in the income statement. For any other biotech built around a flagship drug, track whether new labels and trial wins move revenue, net profit and margin in the same direction as the original thesis.

What argenx’s Recent Run Already Prices In

argenx now trades at €839 after a 22.0% gain over the past year, and the selected Narrative’s Fair Value sits below that level, which reflects that Narrative’s judgment rather than a hard truth.

The Narrative leans on VYVGART as a class-leading FcRn drug with a busy rare-disease pipeline, then asks whether single-asset dependence and pricing pressure can stay contained. A buyer today would need to believe argenx can keep expanding VYVGART across multiple indications without margin erosion from regulation and competition.

"argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases. The investment thesis is based on: ✅ Leadership in a new therapeutic class (FcRn inhibitors) ✅ Very strong commercial growth (revenues doubled in 2 years) ✅ Pipeline with multiple near-term catalysts (2026 to 2027) ⚠️ Typical biotech risks: dependence on a single asset, pricing pressure, competition"

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Before The Next Story Makes Headlines

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 50% below our estimate - targets rapid store expansion and app-based ordering to capture increasing beverage demand.
• Company 2 - 35% below our estimate - benefits as customers seek integrated cybersecurity, communications and defense-technology service contracts.
• Company 3 - 33% below our estimate - converts a large modular and data-center construction pipeline into recurring service work.

Three companies from the same screener. Open all 185 potentially undervalued companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com